节点文献

探讨临床药师参与新型抗肿瘤药物合理使用的切入点

Exploration of the breakthrough point of clinical pharmacists participating in the rational use of new anti-tumor drug

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 卢佳姝李建华

【Author】 LU Jia-shu;LI Jian-hua;Department of Pharmacy,Taizhou People’s Hospital;

【机构】 泰州市人民医院药学部

【摘要】 目的探讨临床药师参与新型抗肿瘤药物临床合理使用的切入点。方法结合临床药师的实际工作,通过对《新型抗肿瘤药物临床应用指导原则》的深入学习,掌握新型抗肿瘤药物的药理作用、药代动力学知识,肿瘤治疗的价值,药物经济学以及合理用药要点,分析并归纳出参与临床合理用药的切入点。结果临床药师制定出包括新型抗肿瘤药物的用药合理性、用药教育、用药安全性评价、医嘱点评等多个切入点。结论临床药师可通过多个切入点参与新型抗肿瘤药物的合理使用,从而更好的开展合理用药工作,保障肿瘤患者的用药安全。

【Abstract】 Objective To explore the breakthrough point for clinical pharmacists to participate in the rational clinical use of new anti-tumor drug. Methods Combined with the actual work of clinical pharmacists, through the "New Anti-tumor Drug Clinical Application Guidelines" in-depth study, to master the pharmacological effects, pharmacokinetics, value of tumor therapy, pharmacoeconomics and key points of rational drug use of new anti-tumor drugs,analyze and conclude the entry point of rational drug use in clinical practice. Results Clinical pharmacists have formulated multiple entry points, including rational use of new anti-tumor drugs, drug education, drug safety evaluation, comments on medical advice and so on. Conclusion Clinical pharmacists can participate in the rational use of new anti-tumor drugs through multiple entry points, so as to better carry out the work of rational drug use and ensure the drug safety of cancer patients.

  • 【文献出处】 中国处方药 ,Journal of China Prescription Drug , 编辑部邮箱 ,2019年12期
  • 【分类号】R979.1
  • 【被引频次】4
  • 【下载频次】388
节点文献中: 

本文链接的文献网络图示:

本文的引文网络